Amgen, Inc. et al. v. USV Pvt., Ltd.
Infringement action filed 25 Mar 2022 in the United States District Court for the District of Delaware and closed 14 Nov 2023, with 3 patents asserted. Recorded basis of termination: case dismissed.
Case record
- Patents involved
- US11162500B2US9820938B2US10344765B2
- Case no.
- 1:22-cv-00387
- Verdict cause
- Infringement action
- Court
- D. Del.
- Court level
- District Court
- Case region
- Delaware
- Chief judge
- Maryellen Noreika
- Trial level
- First instance
- Filed – Closed
- 25 Mar 2022 – 14 Nov 2023
- Duration
- 599 days
- Basis of termination
- Case Dismissed
- Products & marks
- Etelcalcetide injection for intravenous use at strengths of 2.5 mg/0.5 mL, 5 mg/mL, and 10 mg/2 mL
Check this patent against your own product
Prior art, claim scope, infringement exposure and design-around routes. Every answer cites the records behind it.
Get an FTO claim chart- 01Ranked prior artEvery hit source-linked
- 02Claim-level comparisonAgainst your own product
- 03Legal statusAcross 174 jurisdictions
Stable liquid formulation of AMG 416 (etelcalcetide)
A liquid formulation comprising a peptide agonist of the calcium sensing receptor and method of preparing and using the formulation are provided.
- Legal status
- Active
- Granted
- 2 Nov 2021
- Earliest priority
- 28 Jun 2013
- Est. expiry
- 27 Jun 2034
- Validity challenges
- None recorded
- Licences recorded
- None recorded
- Inventors
- MACLEAN, DEREK · YIN, QUN
- Classification
- A61K38/08A61K47/12A61K9/08A61K33/04A61K45/06A61K9/00A61K31/59A61P3/00A61P3/14A61P43/00A61P5/00A61P5/18C07K7/06F04D25/06F01D15/10
- Prosecution counsel
- McDermott Will & Schulte LLP
- Examiner
- HA, JULIE
Stable liquid formulation of AMG 416 (etelcalcetide)
A liquid formulation comprising a peptide agonist of the calcium sensing receptor and method of preparing and using the formulation are provided.
- Legal status
- Active
- Granted
- 21 Nov 2017
- Earliest priority
- 28 Jun 2013
- Est. expiry
- 27 Jun 2034
- Validity challenges
- None recorded
- Licences recorded
- None recorded
- Inventors
- MACLEAN, DEREK · YIN, QUN
- Classification
- A61K47/12C07K7/00A61K9/00A61K31/785A61K33/04A61K45/06A61K31/663C07K7/06A61K38/08A61K38/00A61K9/08A61K31/135A61K31/59
- Prosecution counsel
- McDermott Will & Schulte LLP
- Examiner
- HA, JULIE
Also asserted in this case
1 moreThe docket lists 3 asserted patents. Full bibliographic detail, drawings and prosecution history for the remaining asserted patent are one query away in Eureka.
Parties of record
Amgen, Inc.
- Core tech
- A61K38/08A61K47/12A61K9/08A61K33/04
- Counsel
- Cameron Paul Clark · Jack B. Blumenfeld · Karen Jacobs · Michelle Streifthau-Livizos
- Firm
- Morris, Nichols, Arsht & Tunnell LLP, Saul Ewing Arnstein & Lehr LLP
- Also named
- KAI Pharmaceuticals, Inc.
USV Pvt., Ltd.
- Core tech
- Not recorded
- Counsel
- James Michael Lennon
- Firm
- Devlin Law Firm LLC
Counsel of record
| Attorney | For | Role |
|---|---|---|
| Cameron Paul Clark | Amgen, Inc. | Plaintiff |
| Jack B. Blumenfeld | Amgen, Inc. | Plaintiff |
| Karen Jacobs | Amgen, Inc. | Plaintiff |
| Michelle Streifthau-Livizos | Amgen, Inc. | Plaintiff |
| James Michael Lennon | USV Pvt., Ltd. | Defendant |
Basis of termination
From the record · verbatim“Dismissed per sealed stipulation of dismissal.D.I 186 in 21cv662 (MN)”
Case 1:22-cv-00387 · D. Del. · closed 14 November 2023
Related cases
Three questions this record usually leads to. Each one runs against the full litigation and patent corpus, and cites what it finds.
Frequently asked questions
What is case 1:22-cv-00387?
1:22-cv-00387 is a patent infringement action brought by Amgen, Inc. against USV Pvt., Ltd., filed on 25 Mar 2022 in the United States District Court for the District of Delaware. The case closed on 14 November 2023.
Which patents were asserted in 1:22-cv-00387?
US11162500B2 (“Stable liquid formulation of AMG 416 (etelcalcetide)”), assigned to AMGEN INC., currently active; US9820938B2 (“Stable liquid formulation of AMG 416 (etelcalcetide)”), assigned to AMGEN INC., currently active; US10344765B2 (“Stable liquid formulation of AMG 416 (etelcalcetide)”), assigned to AMGEN INC.. The record also lists Etelcalcetide injection for intravenous use at strengths of 2.5 mg/0.5 mL, 5 mg/mL, and 10 mg/2 mL.
How was case 1:22-cv-00387 terminated?
The recorded basis of termination is case dismissed. The termination text reads: “Dismissed per sealed stipulation of dismissal.D.I 186 in 21cv662 (MN)”
How long did case 1:22-cv-00387 take?
599 calendar days, from filing on 25 Mar 2022 to closure on 14 November 2023.
Who were the attorneys and the judge in 1:22-cv-00387?
Chief Judge Maryellen Noreika presided. Cameron Paul Clark, Jack B. Blumenfeld, Karen Jacobs and Michelle Streifthau-Livizos are recorded as counsel for plaintiff Amgen. James Michael Lennon appears for defendant USV Pvt..
Disclaimer. This page reproduces publicly available court docket data for case 1:22-cv-00387 and is provided for general information and reference only. It is not legal advice and must not be relied upon as such.
Docket data has limits. Records are drawn from a snapshot and may lag the live docket. Sealed filings, amended complaints, counterclaims and post-closure motions may not be reflected. Party names, attorney names and firm affiliations are reproduced as recorded and may contain omissions. Where a field is absent from the record, this page marks it as not recorded rather than inferring a value.
No characterisation of the parties or the outcome. This page reports what the record contains. Nothing here should be read as an assertion that any party infringed, that any patent is valid or invalid, that any settlement occurred, or that any party prevailed.
No FTO or validity opinion. Nothing on this page constitutes a freedom-to-operate, novelty, validity or infringement opinion. Any decision touching a live patent dispute should be verified independently and reviewed with qualified patent counsel.